Patient Satisfaction Up With Pharmacist-Managed Warfarin Tx

This article originally appeared here.
Share this content:
Patient Satisfaction Up With Pharmacist-Managed Warfarin Tx
Patient Satisfaction Up With Pharmacist-Managed Warfarin Tx

TUESDAY, Oct. 4, 2016 (HealthDay News) -- Pharmacist-managed warfarin anticoagulation therapy is associated with improved patient satisfaction, although the benefits in terms of control, safety, and mortality are unclear, according to a review published online Sept. 28 in the Journal of Clinical Pharmacy and Therapeutics.

S. Zhou, M.Pharm., from the Peking University First Hospital in Beijing, and colleagues conducted a systematic review to compare the effectiveness of pharmacist-managed anticoagulation control of warfarin with other models. Data were included from eight randomized controlled trials with a total of 1,493 patients.

The researchers observed a significant difference for satisfaction between pharmacist-managed care and other models (mean difference [MD], 0.41; 95 percent confidence interval [CI], 0.01 to 0.81; P = 0.04), and in the percentage of time within the standard therapeutic range (MD, 3.66; 95 percent CI, 2.20 to 5.11; P < 0.00001). There was no significant improvement in the percentage of time within the expanded therapeutic range (MD, 2.85; 95 percent CI, −0.56 to 6.26; P = 0.10), mortality (odds ratio, 0.97; 95 percent CI, 0.44 to 2.11; P = 0.09), the prevention of bleeding events (odds ratio, 0.89; 95 percent CI, 0.56 to 1.44; P = 0.64), and thrombosis events (odds ratio, 0.81; 95 percent CI, 0.34 to 1.92; P = 0.64) for the pharmacist-managed group.

"Compared with other models, the superiority of pharmacist-managed warfarin anticoagulation needs to be further evaluated and validated in future research," the authors write.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

Belimumab Aids Anti-dsDNA, Hypocomplementemic Lupus

Belimumab Aids Anti-dsDNA&#43;, Hypocomplementemic Lupus

More SLE Responder Index responders at week 52 in the belimumab group versus the placebo group

Too Few Adults Taking Epilepsy Meds Have Seizure Control

Too Few Adults Taking Epilepsy Meds Have Seizure ...

Ninety percent of those with active epilepsy take meds; 44 percent of those report seizure control

Pediatric Exposures to Liquid Nicotine Down From 2015 to 2016

Pediatric Exposures to Liquid Nicotine Down From 2015 ...

Still poses serious risk to children; decrease likely in part to law requiring child-resistant packaging

is free, fast, and customized just for you!

Already a member?

Sign In Now »